Emergex Partners with Brazil’s Bio-Manguinhos to Develop COVID-19 Vaccine

Emergex and Brazil’s Institute of Technology on Immunobiologicals (Bio-Manguinhos) have agreed to work together on “certain immunotherapeutic programs,” including a COVID-19 vaccine.

Emergex will support studies, including clinical trials, and will manufacture, market, promote and distribute certain vaccines within Brazil’s National Health Service, the UK company said.

The COVID-19 vaccine they will co-develop will use Emergex’s synthetic T-Cell vaccine technology. Financial details of the agreement were not disclosed.